Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). - Lundin, J; Kimby, E; Bjorkholm, M; Celsing, F; Hale, G; Hjalmar, V; Merup, M; Petrescu, A; Tullgren, O; Waldmann, H; Mellstedt, H; Osterborg, A (2001)